Immucell reports preliminary Q3 revenue $5.5M vs. $6M last year

“Backlog depletion and buffer stock replenishment appear to have resulted in a one-time lift in sales volume during the first half of 2025,” commented Timothy Fiori, CFO of ImmuCell (ICCC). “Our sales team is aggressively working to rebuild lost market share now that we have the inventory levels needed to support continued growth going forward, and we remain focused on and confident about developing sustainable, long-term growth of the First Defense(R) product line.”